Signal transduction

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

Retrieved on: 
星期二, 八月 3, 2021
Branches of biology, Protein biosynthesis, Biology, aTyr Pharma, Aminoacyl tRNA synthetase, Transfer RNA, Signal transduction

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Key Points: 
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.
  • aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets.
  • aTyrs primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis

Retrieved on: 
星期二, 七月 27, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Tyrosine kinases, Branches of biology, Signal transduction, Pharmaceutical industry, Health sciences, Life sciences, Janus kinase inhibitor, Janus kinase, Jak, Boxed warning, Pharmaceutical industry in China, Medication

Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.

Key Points: 
  • Janus Kinases (JAKs) are enzymes found in cells in the immune system that are critical for the cell signaling process.
  • That is only a fraction of the total market for anti-inflammatory drugs.
  • The FDA has issued Boxed Warnings for one of the marketed JAK inhibitor drugs used in the comparative study.
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations

Retrieved on: 
星期二, 七月 27, 2021
Enzymes, Branches of biology, Signal transduction, Mitogen-activated protein kinase, Ras GTPase, PTPN11, Programmed cell death protein 1, Nivolumab, IRS1, MAPK/ERK pathway

Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.

Key Points: 
  • Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Bristol Myers Squibb will provide nivolumab.
  • Both BridgeBio and Bristol Myers Squibb will share the cost of clinical development activities for the combination trial.
  • SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival.
  • Combination of anti-PD-1 treatment with BBP-398, and other targeted therapies, could be promising for patients with KRAS mutations.

US Radiology Specialists Selects Fujifilm’s Synapse Enterprise Information System to Drive Efficiency and Improve Patient Experience Across its Network

Retrieved on: 
星期一, 七月 26, 2021
Radiological information system, Radiology, Signal transduction, Synapse, Fujifilm, Branches of biology, Optics, Industry economics)

Synapse EIS, based on the foundation of Fujifilms Synapse Radiology Information System (RIS), is a comprehensive workflow management solution designed to streamline physician communication, improve patient interaction, and alleviate administrative burden for the outpatient imaging market.

Key Points: 
  • Synapse EIS, based on the foundation of Fujifilms Synapse Radiology Information System (RIS), is a comprehensive workflow management solution designed to streamline physician communication, improve patient interaction, and alleviate administrative burden for the outpatient imaging market.
  • Synapse EIS exceeded our expectations in terms of scalability, efficiency, and customer ROI and we are excited to extend the Synapse solutions throughout our network.
  • Fujifilms Synapse RIS has been relied upon as the core information system at American Health Imaging and Touchstone Medical Imaging, both US Radiology partners, as those companies experienced exceptional rates of growth over the past 14 years.
  • Learn more about Fujifilms Synapse Enterprise Information System solutions by visiting SynapseEIS.com, and at HIMSS 2021 booth # 3837.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Retrieved on: 
星期三, 七月 14, 2021
Tyrosine kinases, Branches of biology, Signal transduction, Organ systems, Tyrosine kinase 2, Galapagos NV, Psoriasis, Tyrosine kinase, Biology, Janus kinase inhibitor, Janus kinase 3 inhibitor

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

Key Points: 
  • Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
  • Galapagos evaluated GLPG3667, a proprietary selective TYK2 compound, in a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psoriasis.
  • Main objectives were to evaluate the safety and tolerability of GLPG3667 as well as signs of clinical activity at Week 4.
  • Based on these results, we aim to initiate a global Phase 2b program in psoriasis next year as part of a program to develop our selective oral TYK2 inhibitor GLPG3667 broadly in inflammatory indications.

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Retrieved on: 
星期三, 七月 7, 2021
Life sciences, Biology, Branches of biology, Signal transduction, Biotechnology, MTOR, Biopharmaceutical, Cancer

LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021.

Key Points: 
  • LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021.
  • A replay will also be available at this link and posted on Aadis website within the Investors & News/ Events & Presentations section.
  • Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.
  • FYARRO is an investigational drug that has not been approved by the FDA for commercial distribution in the United States.

TYK2 Kinase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
星期三, 七月 7, 2021
Health, Pharmaceutical, Signal transduction, Tyrosine kinases, Tyrosine kinase 2, Pipeline, Tyrosine kinase

The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TYK2 Kinase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "TYK2 kinase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 kinase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different TYK2 kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • TYK2 kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Lysine Specific Demethylase 1 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
星期二, 七月 6, 2021
Health, Pharmaceutical, Enzymes, Demethylase, Signal transduction, KDM7A, Histone demethylase

The "Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lysine Specific Demethylase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine specific demethylase 1 inhibitors pipeline landscape.
  • Lysine specific demethylase 1 inhibitors: Therapeutic Assessment
    This segment of the report provides insights about the different Lysine specific demethylase 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Lysine specific demethylase 1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene

Retrieved on: 
星期三, 六月 30, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Autophagy, Cell death, Immunology, Programmed cell death, Signal transduction, MEK inhibitor, MTOR, Ras GTPase

The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.

Key Points: 
  • The ULK kinase initiates the autophagy pathway and provides a potential targeted approach to selectively inhibiting autophagy in cancers caused by RAS or RAF mutations.
  • In preclinical studies, DCC-3116 was observed to potently and durably inhibit autophagy in RAS and RAF mutant cancer cell lines through the inhibition of ULK kinase.
  • The Phase 1, multicenter, open-label, first-in-human study will evaluate DCC-3116 as a single agent and in combination with trametinib, an FDA-approved MEK inhibitor, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Retrieved on: 
星期二, 六月 29, 2021
Branches of biology, Biology, MTOR, Signal transduction, Tyrosine kinase receptors, Lactams, Protein kinase inhibitors

The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.

Key Points: 
  • The adverse events and overall safety of the trial were consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.
  • In contrast, patients in our ongoing trials receive ANG-3777 within 1-3 days after the targeted organ injury.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.